Analysts See $-0.28 EPS for Cellect Biotechnology Ltd. (APOP)

November 11, 2018 - By Marguerite Chambers

Analysts expect Cellect Biotechnology Ltd. (NASDAQ:APOP) to report $-0.28 EPS on November, 28.They anticipate $0.11 EPS change or 28.21 % from last quarter’s $-0.39 EPS. After having $-0.26 EPS previously, Cellect Biotechnology Ltd.’s analysts see 7.69 % EPS growth. The stock decreased 0.21% or $0.01 during the last trading session, reaching $4.74. About 402 shares traded. Cellect Biotechnology Ltd. (NASDAQ:APOP) has declined 41.02% since November 11, 2017 and is downtrending. It has underperformed by 56.64% the S&P500.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. The company has market cap of $30.86 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. It currently has negative earnings.

More important recent Cellect Biotechnology Ltd. (NASDAQ:APOP) news were published by: which released: “Cellect Bio up 9% premarket ahead of ApoGraft presentation” on November 01, 2018, also published article titled: “40 Stocks Moving In Wednesday’s Mid-Day Session”, published: “Cellect Biotechnology (APOP) Reports Positive Results of Orthopedic Treatment Using ApoGraft on Enriched Stem …” on October 18, 2018. More interesting news about Cellect Biotechnology Ltd. (NASDAQ:APOP) was released by: and their article: “Cellect Bio up 20% premarket enhanced ApoTainer process” with publication date: October 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.